Evidence map›Paper›PMID 25526029›Full record

ArticleOncotarget2014

Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer.

Fubo Wang, Shancheng Ren, Rui Chen, Ji Lu, Xiaolei Shi, Yasheng Zhu, Wei Zhang, Taile Jing, Chao Zhang, Jian Shen and 17 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. LncRNA-Histone Modification Crosstalk: Orchestrating Cancer Pathobiology.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  7. Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment.International journal of molecular sciences · 2025
    Review
  8. Fluorescence imaging of MALAT1 expression using a Cy5.5-labeled antisense oligonucleotide in lung cancer and epidermal carcinoma cells.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Targeting the MALAT1 gene with the CRISPR/Cas9 technique in prostate cancer.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2022
    Article
  19. Review
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Fubo WangDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Shancheng RenDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Rui ChenDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Ji LuDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Xiaolei ShiDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Yasheng ZhuDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Wei ZhangDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Taile JingDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Chao ZhangDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Jian ShenDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China. Department of Urology, Changshu NO. 2 People's Hospital, Changshu, Jiangsu Province, China.
Chuanliang XuDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Huiqing WangDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Haifeng WangDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Yang WangDepartment of Pathology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Bin LiuDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Yaoming LiDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Ziyu FangDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Fei GuoDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Meng QiaoDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Chengyao WuDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Qiang WeiDepartment of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Danfeng XuDepartment of Urology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China.
Dan ShenDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Xin LuDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Xu GaoDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Jianguo HouDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Yinghao SunDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current strategy for diagnosing prostate cancer (PCa) is mainly based on the serum prostate-specific antigen (PSA) test. However, PSA has low specificity and has led to numerous unnecessary biopsies. We evaluated the effectiveness of urinary metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), a long noncoding RNA, for predicting the risk of PCa before biopsy. The MALAT-1 score was tested in a discovery phase and a multi-center validation phase. The predictive power of the MALAT-1 score was evaluated by the area under receiver operating characteristic (ROC) curve (AUC) and by decision curve analysis. As an independent predictor of PCa, the MALAT-1 score was significantly higher in men with a positive biopsy than in those with a negative biopsy. The ROC analysis showed a higher AUC for the MALAT-1 score (0.670 and 0.742) vs. the total PSA (0.545 and 0.601) and percent free PSA (0.622 and 0.627) in patients with PSA values of 4.0-10 ng/ml. According to the decision curve analysis, using a probability threshold of 25%, the MALAT-1 model would prevent 30.2%-46.5% of unnecessary biopsies in PSA 4-10 ng/ml cohorts, without missing any high-grade cancers. Our results demonstrate that urine MALAT-1 is a promising biomarker for predicting prostate cancer risk.

Indexed as

Biomarkers, TumorBiopsyCohort StudiesHumansKallikreinsLogistic ModelsMaleMiddle AgedPolymerase Chain ReactionPredictive Value of TestsProspective StudiesProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesRNA, Long NoncodingBiomarkers, TumorKallikreinsKLK3 protein, humanMALAT1 long non-coding RNA, humanProstate-Specific AntigenRNA, Long Noncoding

Identifiers

PMID25526029
PMCPMC4294360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.